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Protective effects of growth 
hormone‑releasing hormone 
analogs in DSS‑induced colitis 
in mice
Lucia Recinella1, Annalisa Chiavaroli1, Valentina Di Valerio2, Serena Veschi1, 
Giustino Orlando1, Claudio Ferrante1, Iacopo Gesmundo3, Riccarda Granata3, Renzhi Cai4,5,6, 
Wei Sha4,5,6, Andrew V. Schally4,5,6, Rossano Lattanzio7,8, Luigi Brunetti1* & Sheila Leone1*
Besides its metabolic and endocrine effects, growth hormone (GH)‑releasing hormone (GHRH) is 
involved in the modulation of inflammation. Recently synthetized GHRH antagonist MIA‑690 and 
MR‑409, GHRH agonist, developed by us have shown potent pharmacological effects in various 
experimental paradigms. However, whether their administration modify resistance to chronic 
inflammatory stimuli in colon is still unknown. Ex vivo results demonstrated that MIA‑690 and MR‑409 
inhibited production of pro‑inflammatory and oxidative markers induced by lipopolysaccharide on 
isolated mouse colon specimens. In vivo, both MIA‑690 and MR‑409 have also been able to decrease 
the responsiveness to nociceptive stimulus, in hot plate test. Additionally, both peptides also induced 
a decreased sensitivity to acute and persistent inflammatory stimuli in male mice, in formalin test 
and dextran sodium sulfate (DSS)‑induced colitis model, respectively. MIA‑690 and MR‑409 attenuate 
DSS‑induced colitis with particular regard to clinical manifestations, histopathological damage and 
release of pro‑inflammatory and oxidative markers in colon specimens. Respect to MR‑409, MIA‑690 
showed higher efficacy in inhibiting prostaglandin (PG)E2, 8‑iso‑PGF2α and serotonin (5‑HT) levels, 
as well as tumor necrosis factor (TNF)‑α, interleukin (IL)‑6 and nitric oxide synthase gene expression 
in colon specimens of DSS‑induced colitis. Furthermore, MIA‑690 decreased serum insulin‑like 
growth factor (IGF)‑1 levels in mice DSS‑treated, respect to MR‑409. Thus, our findings highlight the 
protective effects of MIA‑690 and MR‑409 on inflammation stimuli. The higher antinflammatory and 
antioxidant activities observed with MIA‑690 could be related to decreased serum IGF‑1 levels.
The hypothalamic peptide growth hormone-releasing hormone (GHRH) stimulates the production and secretion 
of growth hormone (GH) by binding to pituitary type GHRH receptor (GHRH-R)1. GHRH also exerts direct 
extrapituitary  activities2,3, such as  cardioprotection4,5, regeneration of pancreatic  islets6, wound  healing7, as well 
as survival and antiapoptotic  effects8,9. In addition, GHRH acts as an autocrine and/or paracrine growth factor 
in normal non-neoplastic cells and in cancers through the involvement of GHRH-R and its splice variant type 
1 (SV1)1–3,10–12.
Several agonistic and antagonistic analogs of GHRH have been synthesized by our group and others, and 
evaluated for their biological  activities11,13–19. In particular, the new generation GHRH antagonists of the Miami 
(MIA) series, MIA-690 and MIA-602, were shown able to inhibit growth of various human cancer cells and 
 xenografts2,18,20. The most powerful antitumor analogs, MIA-690 and MIA-602 also exerted antinflammatory 
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 activities18,19,21. On the other hand, the MIA-series of GHRH analogs displayed increased GHRH-R binding 
affinity along with a weak GH inhibitory activity on pituitary  somatotrophs18. GHRH agonists of MR series, 
including MR-409, after subcutaneous administration showed increased potency and greater binding activity 
compared with the parent  hormone2,17. Recent studies demonstrated that MR-409 inhibits the in vivo growth of 
lung cancer xenografted into nude  mice17,19.
In this study, we studied the possible antinflammatory and antioxidant properties of GHRH antagonist, MIA-
690, and agonist, MR-409 both ex vivo, through incubation of colon sections with bacterial lipopolysaccaride 
(LPS) and in vivo, following dextran sodium sulfate (DSS) treatment.
Results
Inhibitory effects of MIA‑690 and MR‑409 on LPS‑induced prostaglandin (PG)E2 and 8‑iso‑PGF2α 
levels in colon specimens. PGE2 and 8-iso-PGF2α levels from tissue supernatants were measured by RIA, 
after treatment of colon specimens with LPS + MIA-690 (1 and 5 μM), LPS + MR-409 (1 and 5 μM), LPS or vehi-
cle. We found significantly elevated  PGE2 and 8-iso-PGF2α levels in colon specimens, following treatment with 
LPS, as compared with vehicle-treated controls. The GHRH antagonist MIA-690 (1 and 5 μM) and GHRH ago-
nist MR-409 (1 and 5 μM) were shown to decrease LPS-induced  PGE2 and 8-iso-PGF2α levels, in a dose-depend-
ent manner [Fig. 1 panel A and B; p < 0.05 and p < 0.01 (for MIA-690); p < 0.005 and p < 0.001 (for MR-409)]. 
MR-409 (1 and 5 μM) was more effective than MIA-690 in inhibiting LPS-induced  PGE2 and 8-iso-PGF2α levels 
[Fig. 1 panel A and B; p < 0.05].
Inhibitory effects of MIA‑690 and MR‑409 on LPS‑induced lactate dehydrogenase (LDH) activ‑
ity and nitrite production in colon specimens. In order to investigate the possible effects of MIA-690 
(1 and 5 μM) and MR-409 (1 and 5 μM) on oxidative stress biomarkers, we evaluated LPS-induced LDH activity 
and nitrite production in colon specimens following treatment with the GHRH analogs. LPS treatment sig-
nificantly stimulated LDH activity and nitrite production, respect to vehicle-treated controls. MIA-690 (1 and 
5 μM) reduced LDH activity and nitrite levels in a dose-dependent manner (Fig. 2 panel A and B; p < 0.01 and 
p < 0.005). Moreover, MR-409 (1 and 5 μM) was found able to decrease LPS-induced LDH activity and nitrite 
production, without showing a dose-dependent effect [Fig. 2 panel A and B; p < 0.01]. MIA-690 (5 μM) was more 
effective in inhibiting LDH and nitrite production after LPS treatment respect to MR-409 [Fig. 2 panel A and B; 
p < 0.05].
MIA‑690 and MR‑409 decrease LPS‑induced cyclooxygenase (COX)‑2, nuclear factor 
kappa‑light‑chain enhancer of activated B cells (NF‑kB) and inducible nitric oxide synthase 
(iNOS) gene expression in colon specimens. Real-time polymerase chain-reaction showed signifi-
cantly increased gene expression of COX-2, NF-kB and iNOS in LPS-treated colon specimens, with respect to 
vehicle treated controls. The GHRH antagonist MIA-690 (1 and 5 μM) decreased inflammatory markers after 
LPS treatment in a dose-dependent manner [Fig. 3 panel A, B and C; p < 0.05, p < 0.01, and p < 0.005]. In addi-
Figure 1.  Inhibitory effects of MIA-690 (1 and 5 μM) and MR-409 (1 and 5 μM) on  PGE2 (A) and 8-iso-PGF2α 
(B) levels, ex vivo (n = 5 for each group of treatment). Data are expressed as means ± S.E.M. and analyzed 
by analysis of variance (ANOVA) followed by Bonferroni post-hoc test *p < 0.05, **p < 0.01, ***p < 0.005, 
****p < 0.001 versus LPS; #p < 0.05 versus treatment with MIA-690.
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Figure 2.  Inhibitory effects of MIA-690 (1 and 5 μM) and MR-409 (1 and 5 μM) on LDH activity (A) and 
nitrite production (B), ex vivo (n = 5 for each group of treatment). Data are expressed as means ± S.E.M. and 
analyzed by analysis of variance (ANOVA) followed by Bonferroni post-hoc test *p < 0.05, **p < 0.01, ***p < 0.005 
versus LPS; #p < 0.05 versus treatment with MR-409.
Figure 3.  Relative quantification of COX-2 (A), NF-kB (B) and iNOS (C) gene expression in mouse colon 
specimens treated with MIA-690 (1 and 5 μM) and MR-409 (1 and 5 μM), ex vivo (n = 5 for each group of 
treatment). Data were calculated using the  2-ΔΔCt method, normalized to β-actin mRNA levels, and expressed 
relative to control (calibrator sample, defined as 1.00). Data are expressed as means ± S.E.M. and analyzed by 
analysis of variance (ANOVA) followed by Bonferroni post-hoc test *p < 0.05, **p < 0.01, ***p < 0.005 versus LPS; 
#p < 0.05 versus treatment with MR-409.
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tion, GHRH agonist MR-409 (1 and 5 μM) was found able to decrease LPS-induced gene expression of COX-2, 
NF-kB and iNOS in colon specimens, without a dose-dependent effect [Fig. 3 panel A, B and C; p < 0.01]. MIA-
690 (5 μM) was more effective than MR-409 in inhibiting all tested markers [Fig. 3 panel A, B and C; p < 0.05].
MIA‑690 and MR‑409 reduce nociceptive response in mice. With the objective to determine the 
responsiveness to acute nociceptive stimulation, mice were tested by conventional hot plate apparatus at the 
temperature of 54.0 ± 0.4 °C. MIA-690 (5 μg) or MR-409 (5 μg) were s.c. treated daily for 4 weeks in mice. Con-
trol animals received s.c. injection of vehicle (0.1% DMSO (Sigma) and 10% propylene glycol). The evaluations 
were performed after 2 and 4 weeks of treatment. Compared to vehicle, both GHRH analogs showed maximal 
antinociceptive effects of 16.26% and 21.75% M.P.E. at 2 weeks [Fig. 4; p < 0.05 and p < 0.01, respectively]. Both 
peptides also sustained a moderate analgesic effect at 4 weeks, with maximal antinociceptive effect of 16.41 and 
21.49% M.P.E. [Fig. 4; p < 0.05 and p < 0.01, respectively]. MR-409 showed greater effects respect to MIA-690 
[Fig. 4; p < 0.05] at both 2 and 4 weeks.
Figure 4.  Effect of MIA-690 (5 µg) and MR-409 (5 µg) (n = 6 for each group of treatment) s.c. administration 
on the analgesic response at the temperature of 54.0 ± 0.4 °C in hot plate test. The antinociceptive activity is 
expressed as percentage of the maximum possible effect (% M.P.E.). Data are expressed as means ± S.E.M. and 
analyzed by analysis of variance (ANOVA) followed by Bonferroni post-hoc test *p < 0.05, **p < 0.01 versus 
vehicle; #p < 0.05 versus MIA-690.
Figure 5.  Effect of MIA-690 (5 µg) and MR-409 (5 µg) s.c. administration on the acute nociceptive response in 
formalin test (n = 6 for each group of treatment). The nociceptive behaviour time (seconds) of licking, shaking 
and biting was measured during the period of 0–5 min (first phase) and 20–60 min (second phase). Data are 
expressed as means ± S.E.M. and analyzed by analysis of variance (ANOVA) followed by Bonferroni post-hoc test 
*p < 0.05, **p < 0.01 versus vehicle; #p < 0.05 versus MIA-690.
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MIA‑690 and MR‑409 reduce responsiveness to acute inflammation stimuli. With the aim to 
determine the responsiveness to acute inflammation stimulation mice were tested by formalin test. MIA-690 
(5 μg) or MR-409 (5 μg) were s.c. injected daily for 4 weeks in mice. Control animals received s.c. injection of 
vehicle (0.1% DMSO (Sigma) and 10% propylene glycol). The evaluations were performed after 2 and 4 weeks of 
treatment. After intraplantar injection of formalin, mice treated with MIA-690 (5 μg) or MR-409 (5 μg) showed 
short nociceptive behavioural responses (first and second phase) compared to vehicle groups [Fig. 4; p < 0.05 and 
p < 0.01], at both 2 and 4 weeks. In second phase, we showed that s.c. injection of MR-409 significantly decreased 
nociceptive behavioural response at both 2 and 4 weeks of treatment compared to MIA-690 [Fig. 5; p < 0.05].
MIA‑690 and MR‑409 reduce disease activity index (DAI) score and colon length in DSS‑induced 
colitis. DSS (2.5%)-induced colitis was induced to investigate the potential effects of MIA-690 (5 μg) and 
MR-409 (5 μg) on inflammatory stimuli. DSS treatment led to higher DAI score in all treated groups as com-
pared to controls (mice untreated with DSS). MIA-690 (5 μg) or MR-409 (5 μg) treated mice displayed signifi-
cantly lower susceptibility to DSS treatment starting from day 2 [Fig. 6, panel A; p < 0.01 and p < 0.005]. However, 
treatment with MIA-690 (5 μg) or MR-409 (5 μg) did not induce a significant reduction in mortality respect to 
vehicle treated animals (n = 1/10 for all groups; data not shown).
In our model, we observed a significant reduction in colon segment length in all groups treated with DSS 
respect to positive controls (mice untreated with DSS). MIA-690 (5 μg) or MR-409 (5 μg) treated mice showed a 
minor decrease in colon segment length respect to DSS treated animals, suggesting that both peptides induce a 
lower sensitivity to chronic inflammation stimuli [Fig. 6, panel B; p < 0.05]. No significant difference was found 
between MIA-690 and MR-409 treated mice in DAI score and colon segment length.
Macroscopic and histopathological examination. Representative macroscopic and histological 
images of H&E-stained colon sections from each group are shown in Fig. 7. Respect to normal colon (positive 
Figure 6.  Effect of MIA-690 (5 µg) and MR-409 (5 µg) (n = 6 for each group of treatment) s.c. administration 
on relative DAI scores (A) and colon segment lengths (B) in a model of DSS-induced colitis. Data are expressed 
as means ± S.E.M. and analyzed by analysis of variance (ANOVA) followed by Bonferroni post-hoc test *p < 0.05, 
**p < 0.01, ***p < 0.005 versus DSS-treated mice.
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Figure 7.  Effect of MIA-690 (5 µg) and MR-409 (5 µg) (n = 6 for each group of treatment) s.c. administration on 
macroscopic and histopathological changes of colon in a model of DSS-induced colitis. A (a1 and a2): normal 
colon segment; B (b1 and b2), C (c1 and c2) and D (d1 and d2): inflammation of colon segment in DSS-induced 
colitis; necrosis of epithelium, distortion of crypts, inflammation, infiltrates in lamina propria and submucosa 
as well as submucosal edema. Hematoxilyn and eosin stain: the inserted bars indicate magnification. [H&E 
staining, × 10 (a1, b1, c1, d1); × 20 (a2, b2, c2, d2) original magnification].
Figure 8.  Inhibitory effects of MIA-690 (5 g) and MR-409 (5 μg) on prostaglandin  E2 (A) and 8-iso-
prostaglandin  F2α (B) levels in colon segment of DSS-induced colitis (n = 6 for each group of treatment). Water 
group were control mice untreated with DSS. Data are expressed as means ± S.E.M. and analyzed by analysis of 
variance (ANOVA) followed by Bonferroni post-hoc test *p < 0.05 **p < 0.01,***p < 0.005 versus water controls; 
#p < 0.05 versus MR-409 treated mice.
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control Ctrl; Fig. 7A, panel a1 and a2), we observed high (vehicle; Fig. 7B, panel b1 and b2), low (MIA-690; 
Fig. 7C, panel c1 and c2) and moderate (MR-409; Fig. 7D, panel d1 and d2) inflammation. In positive control 
(Ctrl; Fig. 7B, panels b1 and b2 and) we found that DSS treated mice showed an important necrosis of the epi-
thelium and submucosal edema in positive control. These changes were associated with marked infiltration of 
inflammatory cells in the lamina propria and submucosa. The infiltrated inflammatory cells included polymor-
phonuclear leucocytes, lymphocytes, and plasma cells.
In addition, histological analysis showed lower inflammation in mice treated with MIA-690 (5 µg) (Fig. 7 
C, panel c1 and c2). Despite a weak infiltration of lymphocytes into the mucosal tissue, crypt damage was not 
observed. Moreover, the animals treated with MR-409 (5 µg) showed moderate lymphocytic infiltrate and impor-
tant crypt destruction in histological examination (Fig. 7D; panel d1 and d2).
MIA‑690 and MR‑409 decreased  PGE2 and 8‑iso‑PGF2α levels in colon specimens of DSS‑induced 
colitis. In order to study the possible effects of MIA-690 (5 μg) and MR-409 (5 μg) on inflammatory and 
oxidative stress biomarkers, we determined  PGE2 and 8-iso-PGF2α levels in colon specimens from DSS-treated 
mice. DSS treatment significantly stimulated both  PGE2 and 8-iso-PGF2α levels, and both MIA-690 (5 µg) and 
MR-409 (5 µg) reduced these effects, with MIA-690 more active respect to MR-409 [Fig. 8; p < 0.005; p < 0.01 and 
p < 0.05].
Effects of MIA‑690 and MR‑409 on serotonin (5‑hyroxytriptamine, 5‑HT) and kynurenic acid 
(KA) levels in colon specimens of DSS‑induced colitis mice. We also investigated the potential effects 
of MIA-690 (5 μg) and MR-409 (5 μg) on 5-HT and KA production in colon specimens from DSS-treated mice. 
In this context, s.c. administration of MIA-690, but not MR-409, significantly decreased 5-HT levels [Fig. 9; 
p < 0.05]. On the other hand, both peptides significantly reduced KA levels [Fig. 9; p < 0.05].
Effects of MIA‑690 and MR‑409 on tumor necrosis factor (TNF)‑α, interleukin (IL)‑6 and iNOS 
gene expression in colon specimens of DSS‑induced colitis mice. Real-time polymerase chain-
reaction showed a significant increase in TNF-α, IL-6 and iNOS mRNA levels in all groups, as compared with 
controls. MIA-690 (5 µg) decreased TNF-α, IL-6 and iNOS gene expression, while MR-409 (5 µg) did not modify 
IL-6 and was less effective than MIA in reducing TNF-α, and iNOS [Fig. 10; p < 0.05, p < 0.01].
Effects of MIA‑690 and MR‑409 on serum insulin‑like growth factor (IGF)‑1 levels. ELISA 
results showed a significant reduction in circulating levels of IGF-1 in MIA-690 (5 μg) treated mice, but not in 
MR-409 (5 μg) treated mice (Fig. 11; p < 0.05).
Discussion
Our present findings showed that MIA-690, a GHRH antagonist, and MR-409, an agonistic GHRH analog, exert 
antinflammatory and antioxidant effects on colon specimens, ex vivo (Figs. 1, 2 and 3). In agreement, a number 
of studies demonstrated that GHRH and GHRH antagonists can modulate the inflammatory and reduction/
Figure 9.  Effects of MIA-690 (5 µg) and MR-409 (5 μg) on 5-HT (A) and KA (B) levels in colon segments of 
DSS-induced colitis mice (n = 6 for each group of treatment). Data are expressed as means ± S.E.M. and analyzed 
by analysis of variance (ANOVA) followed by Bonferroni post-hoc test *p < 0.05 **p < 0.01 versus DSS treated 
mice; #p < 0.05 versus MR-409 treated mice.
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oxidation (redox) status in cancer and other  tissues22,23. In particular, MIA-690 has proved able to decrease 
inflammation by suppressing the infiltration of macrophages and leucocytes, and the secretion of TNF-α, IL-1β, 
and monocyte chemotactic protein-1 (MCP-1) in aqueous humor after insult with  LPS24. Moreover, MIA-690 
Figure 11.  Effects of MIA-690 (5 μg) and MR-409 (1-5 μM) on IGF-1 levels in serum of DSS-treated mice (n = 6 
for each group of treatment) as determined by ELISA kit. Data are expressed as means ± S.E.M. and analyzed 
by analysis of variance (ANOVA) followed by Bonferroni post-hoc test *p < 0.05 versus water controls, DSS or 
DSS + MR-409 treated mice.
Figure 10.  Effects of MIA-690 (5 μg) and MR-409 (5 μg) on relative gene expression of TNF-α, IL-6 and iNOS 
in colon segment of DSS-treated mice (n = 6 for each group of treatment) as determined by real-time RT PCR. 
Data were calculated using the  2−ΔΔCt method; normalized to β-actin mRNA levels and then expressed as relative 
to control (calibrator sample, defined as 1.00). Data are expressed as means ± S.E.M. and analyzed by analysis 
of variance (ANOVA) followed by Bonferroni post-hoc test *p < 0.05 and **p < 0.01 versus DSS treated mice; 
#p < 0.05 and ##p < 0.01 versus MR-409 treated mice.
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exerted antinflammatory and antioxidant effects in different experimental  paradigms25,26. MIA-690 was also 
found able to decrease the expression of proinflammatory and oxidative markers, such as COX-2, TNF-α, NF-kB, 
iNOS and Nrf2, in ex vivo and in vivo  studies26. Similarly, MR-409 also showed antinflammatory and antioxidant 
 effects26, with neural and vascular protective properties in early experimental diabetic  retinopathy27. Interestingly, 
the authors hypothesized that the beneficial effects induced by MR-409 could be direct and/or GH-mediated.
Firstly, the responsiveness to nociceptive and acute inflammation stimuli was evaluated following chronic 
administration of MIA-690 and MR-409 in vivo. We found that both peptides induce analgesic and antinflamma-
tory effects after chronic treatment, both at 2 and 4 weeks of treatment (Figs. 4, 5). The role of the somatotropic 
axis in analgesia is contradictory, with scant data relative to GHRH. Receptors for GH and IGF-1 and -2 are 
expressed in the hippocampus, a brain region involved in pain  perception28 and various studies have reported the 
link between endogenous opiates and GHRH in the human  hypothalamus29. Interestingly, both GHRH agonist 
and antagonist analogs showed similar antinociceptive activities. However, the agonist peptide MR-409 showed 
higher antinociceptive effects with respect to the antagonist MIA-690 at both 2 and 4 weeks (Fig. 4). GHRH has 
been shown to bind to opioid  receptors30, and we have previously shown that generalized ablation of the GHRH 
gene (GHRHKO) increases sensitivity to thermal pain, in  mice31.
On the other hand, mice treated with both peptides showed also a lower responsiveness after intraplantar 
formalin injection (Fig. 5). The involvement of the somatotropic axis in inflammatory states is well  known32,33. 
Various agonist and antagonist analogs of GHRH have shown marked antinflammatory  effects16,19,27,34–36. In 
particular, MIA-690 inhibited inflammation by reducing the production of inflammatory markers in carrageenan-
induced chronic  prostatitis35. Moreover, pre-treatment with GHRH was found to suppress endotoxin-induced 
inflammatory hyperalgesia in animal  models37. In addition, GHRHKO mice showed a significantly increased 
sensitivity to inflammatory  stimuli31.
These data have allowed us to perform our study on DSS-induced colitis.
Finally, in our model of DSS-induced colitis, animals treated with both MIA-690 and MR-409 displayed lower 
DAI score and a significant increase in colon segment length as compared with vehicle (Fig. 6). However, we did 
not observe any difference in mortality between groups, probably due to the short duration of treatment with 
DSS. In this context, the antinflammatory effects of MIA-690 were more marked respect to MR-409. MIA-690 
decreased the infiltration of lymphocytes into mucosal tissue (Fig. 7, panel c1 and c2),  PGE2, 8-iso-PGF2α and 
5-HT levels (Figs. 8 and 9), as well as TNF-α, IL-6 and iNOS gene expression (Fig. 10) in colon specimens. Despite 
both peptides showed similar effects on DAI score and colon segment length, MR-409 did not significantly 
decrease the inflammatory response (Fig. 7). In particular, histological analysis showed a moderate increase of 
crypt destruction and infiltration of lymphocytes in the mucosa, with respect to vehicle or MIA-690 treatment 
(Fig. 7, panel d1 and d2). However, MR-409 decreased all inflammatory markers, except 5-HT and IL-6 (Figs. 9 
and 10). Our results are in agreement with those of Ren and collaborators (2019) showing that another GHRH 
antagonist of MIAMI series, MIA-602, was found able to suppress elevated expression of some pro-inflammatory 
cytokines, including IL-6, and iNOS, in ciliary and iris epithelial cells during LPS-induced ocular inflammation; 
while these effects were not observed for MR-40938.
5-HT is involved in the pathogenesis of intestinal disorders, including  IBD39–41, irritable bowel  syndrome39,42,43 
and DSS-induced experimental  colitis44. In addition, IL-6 is up regulated in  colitis45–48 and it has been shown to 
be positively correlated with disease severity in  IBD49. The lower antinflammatory effects of MR-409 with respect 
to MIA-690 could be explained by lack of effects on 5-HT and IL-6 levels.
IGF-1, in addition to its well-established growth and metabolic effects, is also involved in inflammatory 
processes and immune cell  recruitment50. In particular, IGF‐1 enhances intestinal inflammation and inflamma-
tion‐associated  tumorigenesis50. Following MIA-690 treatment in mice, we found a reduction of serum IGF-1 
levels (Fig. 11). In this context, Schally and collaborators (2008) reported that GHRH antagonists suppressed the 
release of GH from pituitary through binding to the GHRH receptors and blocked the production and release of 
 GH16. Thereafter, the reduction in serum IGF-1 could be a consequence of blocking the secretion of GH, as previ-
ously observed in other  works20,25. The IGF‐1 pathway has been finely related to cancer and IBD, by regulating 
the immune system and through its multifunctional involvement in tumor  microenvironment51. Aberrant IGF‐1 
signaling has been observed in several cancers in humans, with the involvement of IGF‐1 receptor signaling in 
cancer cell proliferation, migration, and invasion as well as in resistance to therapeutic  agents50,52–55.
On the other hand, MR-409 did not affect serum IGF-1 levels. Our findings could be explained by a transient 
stimulatory effect induced by MR-409 on GH release, previously reported by Cui and Schally (2018)56. A reduc-
tion in serum IGF-1 levels was shown from 24 h on day 1 to day 5, in C57BL/6 mice treated with MR-409 (5 μg/
day) for 15  days56. However, after day 10, no change was found in serum levels of IGF-1 in the animals treated 
with MR-409 compared to  controls56. Accordingly, except for the first hour, no significant difference in GH 
levels was shown between MR-409- and control-treated  mice56. In addition, no significant change in serum GH 
levels was previously reported in MR-409-treated animals bearing three types of lung  cancer19. Our results are 
also in agreement with those of Qin and collaborators (2014) showing that IGF-1 levels in aqueous humor was 
significantly decreased after treatment with MIA-690, but not MR-409, in experimental ocular  inflammation57. 
Moreover, GHRH agonists did not modify serum levels of IGF-1 in rats following 4 week-treatment, compared 
to placebo-treated  animals58,59. On the other hand, GH/IGF-1 independent effects were previously reported for 
GHRH agonists, including MR-40958,59. The inhibitory effects of MIA-690 on serum IGF-1 levels could partially 
explain the higher antinflammatory and antioxidant effects displayed by this peptide as compared to MR-409.
In conclusion, both GHRH antagonist MIA-690 and agonist MR-409 show antinflammatory and antioxi-
dant properties in ex vivo experimental models. Both peptides also decrease thermal sensitivity and chemical 
responsiveness to acute and persistent inflammatory stimuli, in in vivo studies. The higher antinflammatory 
and antioxidant activities observed for MIA-690 could be related to decreased serum IGF-1 levels. However, we 
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can not rule out a possible involvement of GH/IGF-1 independent effects in modulation of protective activities 
induced by MIA-690.
Methods
Peptides and chemicals. The GHRH antagonist MIA-690 and agonist MR-409 were synthesized by R.C. 
and W.S. in the laboratory of one of us (A.V.S.). For ex vivo studies, the peptides were dissolved in DMSO to 
form a 5 mM solution, and then further diluted to the concentration indicated. For in vivo studies, the peptides 
were dissolved in an aqueous solution of 0.1% DMSO (Sigma) and 10% propylene glycol (Sigma-Aldrich, St. 
Louis, MO)19,25.
Animals. Adult C57/BL6 male mice (5 weeks old, weight 20–22 g, n = 48 were housed in Plexiglas cages (2–4 
animals per cage; 55 × 33 × 19 cm), on a 14/10 h light/dark cycle, with ad libitum access to water and food. Only 
male mice were used to avoid any possible involvement of hormonal changes in adult female mice. Mice were 
fed with a standard rodent chow (Prolab RMH2500, PMI Nutrition International, Brentwood, MO). Housing 
conditions and experimentation procedures were strictly in agreement with the European Community ethical 
regulations (EU Directive n. 26/2014) on the care of animals for scientific research. The study was carried out in 
compliance with the ARRIVE guidelines. In agreement with the recognized principles of “Replacement, Refine-
ment and Reduction of Animals in Research”, colon specimens were obtained as residual material from vehicle-
treated mice randomized in our previous experiments approved by Local Ethical Committee (‘G. d’Annunzio’ 
University, Chieti-Pescara) and Italian Health Ministry (Project n. 885/2018-PR).
Ex vivo studies. Mice were sacrificed by  CO2 inhalation (100%  CO2 at a flow rate of 20% of the chamber 
volume per min) and colon was immediately collected and maintained in a humidified incubator with 5%  CO2 at 
37 °C for 4 h (incubation period), in RPMI buffer with added bacterial LPS (10 μg/mL), as previously  described60. 
During the incubation period, the tissues were treated with MR-409 or MIA-690 (1–5 μM). Tissue supernatants 
were collected and prostaglandin (PG)  E2 and 8-iso-PGF2α levels (pg/mg wet tissue) were measured by radioim-
munoassay (RIA), as previously  reported60. Briefly, specific anti-PGE2 and anti-8-iso-PGF2α were developed in 
the rabbit; the cross-reactivity against other prostanoids was < 0.3%. One hundred microliters of prostaglandin 
standard or sample was incubated overnight at 4 °C with  the3H-prostaglandin (3000 cpm/tube; NEN) and anti-
body (final dilution: 1:120 000; kindly provided by the late prof. G. Ciabattoni), in a volume of 1.5 mL of 0.025 M 
phosphate buffer. Free and antibody-bound prostaglandins were separated by the addition of 100 μL 5% bovine 
serum albumin and 100 μL 3% charcoal suspension, followed by centrifugation for 10 min at 4000 g at 5 °C and 
decanting off the supernatants into scintillation fluid (UltimaGold Perkin Elmer) for β emission counting. The 
detection limit of the assay method was 0.6 pg/mL. Tissue supernatants were also assayed for nitrite determina-
tion by Griess assay, as previously  described26. Briefly, nitrite production was determined by mixing 50 μL of the 
assay buffer with 50 μL of Griess reagent (1.5% sulfanilamide in 1 M HCl plus 0.15% N-(1-naphthyl) ethylenedi-
amine dihydrochloride in distilled water, v/v). After incubation for 10 min, at room temperature, the absorbance 
at 540 nm was determined and nitrite concentrations were calculated from a standard curve for sodium nitrite.
Tissue supernatants were also assayed for LDH  activity26. LDH activity was measured by evaluating the 
consumption of NADH in 20 mM HEPES-K + (pH 7.2), 0.05% bovine serum albumin, 20 μM NADH and 
2 mM pyruvate using a microplate reader (excitation 340 nm, emission 460 nm) according to manufacturer’s 
protocol (Sigma-Aldrich, St. Louis, MO). LDH activity was measured by evaluating the consumption of NADH 
in 20 mM HEPES-K + (pH 7.2), 0.05% bovine serum albumin, 20 μM NADH and 2 mM pyruvate using a 
microplate reader (excitation 340 nm, emission 460 nm) according to manufacturer’s protocol. Nitrite and LDH 
production data were expressed as relative variations compared to vehicle-treated specimens. Immediately after 
sacrifice, colon specimens were rapidly removed, dissected and stored in RNAlater solution (Ambion, Austin, 
TX) at -20 °C until further processed. Total RNA was extracted from the colon specimens using TRI Reagent 
(Sigma-Aldrich), according to the manufacturer’s protocol. One microgram of total RNA extracted from each 
sample in a 20 µl reaction volume was reverse transcribed using High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). The samples were incubated in a 2720 Thermal Cycler (Applied Biosystems) initially at 
25 °C for 10 min, then at 37 °C for 120 min, and finally at 85 °C for 5 s. Gene expression of COX-2, NF-kB and 
iNOS was determined by quantitative real-time PCR using TaqMan probe-based chemistry (Applied Biosystems), 
as previously  described61,62. PCR primers and TaqMan probes were obtained from Applied Biosystems [Assays-
on-Demand Gene Expression Products, Mm00478374_m1 for COX-2 gene, Mm00476361_m1 for NF-kB gene, 
Mm00440502_m1 for iNOS gene, Mm00607939_s1 for β-actin gene]. β-actin was used as the housekeeping gene. 
Gene expression data were calculated as previously  reported63.
In vivo studies. After 2-week acclimation, mice were treated daily by subcutaneous (s.c.) administration of 
0.1 ml solution of GHRH antagonist MIA 690 (5 µg), GHRH agonist MR 409 (5 µg) or  vehicle20. All solutions 
were freshly prepared before use. The concentrations were selected based on previous  studies19,20. All treatments 
were administered at 09:00 a.m., and all in vivo testings were performed between 10:00 a.m. and 12:00 a.m. to 
minimize circadian variations in sensitivity to  pain64. Care was taken to standardize testing  conditions65. The 
experimental room was maintained with minimal background noise and constant temperature (22 ± 2 °C). All 
materials used for each test were thoroughly cleaned after test completion for each mouse. At the end of each 
test, the animals were returned to their home cages, and the apparatus was cleaned with 75% ethanol and dried 
before the next procedure. Antinociceptive and antinflammation testing was performed at 2 and 4 weeks after 
the first injection. Each test was conducted on the same group of animals (n = 6 for each group of treatment), 
after a 2-week rest period to avoid any interference on behavioral test performance, as previously  reported66.
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Hot plate test. Basal responsiveness to nociceptive stimulation was measured by hot-plate apparatus (2bio-
logical Instruments, Varese, Italy), set at the temperature of 54.0 ± 0.4 °C, as previously  described31. The antino-
ciceptive response was the latency from placement of the mouse on the heated surface until the first overt behav-
ioral sign of nociception, such as (i) licking a hind paw, (ii) vocalization, or (iii) an escape attempt (jumping off 
the plate). The timer was stopped by a foot-operated pedal and the mouse was immediately removed from the 
hot-plate immediately after responding or after a maximum of 30 s (cut-off), to prevent tissue damage. In our 
conditions, the baseline latencies obtained in pre-experimental tests, ranged from 5.1 ± 0.7 to 6.2 ± 0.8 s. The 
analgesic effect was calculated as a percentage of the maximum possible effect (%M.P.E.) according to the for-
mula: (TL-BL)/(30-BL) × 100, where TL = test latency, BL = baseline latency, 30 = cut-off time in seconds.
Formalin test. A diluted formalin solution was injected subcutaneously under the plantar surface of a hind 
paw, and pain related behaviors were scored during two successive  phases31. The first phase (0–5 min.) reflects 
direct activation of nociceptors and therefore provides a measure of acute chemical pain. The second phase 
(20–60 min) mainly reflects persistent pain that is associated with developing inflammatory response within 
the injected paw. Each mouse was placed in a transparent Plexiglas box (17.5 × 23.5 × 9.5 cm) positioned above a 
mirror to allow an unobstructed view of the paw. After a 15-min habituation period, formalin (10 μl of a 3% solu-
tion in saline) was injected under the plantar surface of the right hind paw, using a 50 μl Hamilton microsyringe 
with a 25-gauge needle. The mouse was placed back into the box immediately after the injection and behavioral 
scoring consisted of either counting the number of nociceptive responses (paw licking, shaking and biting) or 
measuring how long the animal produced these responses.
DSS‑induced colitis. Male mice were randomized into three groups and treated daily for 7 days. Colitis 
was induced by 2.5% (w/v) DSS (molecular weight 40 kDa; Sigma Aldrich, Steinheim, Germany) added to the 
drinking water, ad libitum for 7  days31. C57BL/6 (n = 6) mice untreated with DSS were used as positive control.
Colitis DAI analysis. Colitis DAI scoring was calculated as previously  described67. DAI score was the com-
bined score of weight loss (0, none; 1, 0–5%; 2, 5–10%; 3, 10–20%; and 4, > 20%), stool consistency change (0, 
none; 2, loose stool; and 4, diarrhea), and bleeding (0, none; 1, trace; 2, mild hemoccult; 3, obvious hemoccult; 
and 4, gross bleeding), and then divided by three. The minimal score was 0 and the maximal score was 4. The 
animals were scored for the DAI at the same time of each day, and DAI score was recorded every day. Animals 
were treated with anesthetic and analgesic drugs [caprofen 10 mg/kg; meloxicam 10 mg/kg; lidocaine (1–2%) 
2–4 mg/kg] when they displayed signs of distress, according to the guidelines suggested by the ‘National Centre 
for the Replacement, Refinement and Reduction of Animals in Research’ (NC3RS).
Macroscopic and histological evaluation. Mice were sacrificed by  CO2 inhalation (100%  CO2) at a flow 
rate of 20% of the chamber volume per min), individual colon was dissected and the colon segment length (from 
ileocecal junction to the anal verge; mm) measured by a ruler. Tissues were fixed in 10% phosphate-buffered 
formalin, dehydrated in a series of alcohol solutions of 50%, 70%, 95% and 99% and then in xylene. Samples 
were then paraffin-embedded and cut in 5 μm-thick sections. Sections were de-waxed (xylene and alcohol in 
progressively lower concentrations), rehydrated and processed for Hematoxylin and Eosin (H&E) staining (Bio 
Optica, Milano, Italy) according to the manufacturer protocol.
H&E-stained 5 mm distal colonic sections were coded for blind microscopic assessment of inflammation. 
Samples were then observed by means of Leica DM 4000 microscope (Leica Cambridge Ltd, Cambridge, UK) 
equipped with a Leica DFC 320 camera (Leica Cambridge Ltd.) for computerized images.
PGE2 and 8‑iso‑PGF2α production in isolated colon specimens. PGE2 and 8-iso-PGF2α levels (ng/
mg wet tissue) in isolated colon specimens of mice treated with MIA-690 (5 µg) andMR-409 (5 µg) were evalu-
ated by radioimmunoassay (RIA), as previously  reported31. Colon specimens dissected from C57BL/6 (n = 6) 
mice untreated with DSS were used as positive control.
5‑HT and high performance liquid chromatography (HPLC) determination. Tissue 5-HT levels 
were analyzed through an HPLC apparatus consisting of a Jasco (Tokyo, Japan) PU-2080 chromatographic pump 
and an ESA (Chelmsford, MA, USA) Coulochem III coulometric detector, equipped with microdialysis cell 
(ESA-5014b) porous graphite working electrode and solid-state palladium reference electrode. The analytical 
conditions for identification and quantification were selected according to a previous study. Briefly, the analytical 
cell was set at -0.150 V, for detector 1 and at + 0.300 V for detector 2, with a range of 100 nA. The chromatograms 
were monitored at the analytical detector 2. Integration was performed by Jasco Borwin Chromatography soft-
ware, version 1.5. The chromatographic separation was performed by isocratic elution on Phenomenex Kinetex 
reverse phase column (C18, 150 mm × 4.6 mm i.d., 2.6 µm). As regards separation of 5-HT, the mobile phase 
was (10:90 v/v) acetonitrile and 75 mM pH 3.00 phosphate buffer containing octanesulfonic acid 1.8 mM, EDTA 
30 µm and triethylamine 0.015% v/v. Flow rate was 0.6 ml/min and the samples were manually injected through 
a 20 µl loop. Analyte peaks were identified by comparison with the retention time of pure standard. Analyte 
concentrations in the samples were calculated by linear regression curve (y = bx + m) obtained with standard. 
The standard stock solution of 5-HT at 2 mg/ml was prepared in bidistilled water containing 0.004% EDTA 
and 0.001% sodium bisulfite. The stock solutions were stored at 4 °C. Work solutions (1.25–20.00 ng/ml) were 
obtained by progressively diluting the stock solutions in the mobile phase.
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KA and HPLC‑Fluorimetric Determination. The KA quantitative determination in the tissue was car-
ried out a reversed phase HPLC-fluorimeter in agreement with the method employed by Pocivavsek and col-
leagues. Analyses were performed by using a liquid chromatograph (MOD. 1525, Waters Corporation, Milford 
MA, USA) equipped with a fluorimetric detector (MOD, 2475, Waters Corporation), a C18 reversed-phase 
column (Acclaim 120,3 µm, 2.1 × 100 mm, Dionex Corporation Sunnyvale, CA, USA), and an on-line degasser 
(Biotech 4-CH degasi compact, LabService, Anzola, Italy). The separation was conducted in isocratic condi-
tions and the mobile phase consisted of 250 mM zinc acetate, 50 mM sodium acetate, and 3% aceto nitrile (pH 
adjusted to 6.2 with glacial acetic acid), using a flow rate of 1.0 mL/min. In the eluate, the KA was identified and 
measured fluorimetrically (excitation: 344 nm; emission: 120 nm).
RNA extraction, reverse transcription and real‑time reverse transcription polymerase chain 
reaction (real‑time RT PCR). Colon tissue was rapidly removed, dissected and stored in RNAlater solu-
tion (Ambion, Austin, TX) at -20 °C until further processed as previously described. Gene expression of TNF-α, 
IL-6 and iNOS was determined by quantitative real-time PCR using TaqMan probe-based chemistry (Applied 
Biosystems, Foster City, CA, USA). PCR primers and TaqMan probes were obtained from Applied Biosystems 
(Assays-on-Demand Gene Expression Products, Mm00443258_m1 for TNF-α gene, Mm00446190_m1 for IL-6 
gene, Mm00440502_m1 for iNOS gene, Mm00607939_s1 for β-actin gene. β-actin was used as the housekeeping 
gene. Gene expression data were calculated as previously  reported63.
IGF‑1 Analysis. Blood sample (1 ml) collection was performed through cardiac puncture in mice. Serum, 
obtained by centrifugation of total blood at 450 g at 4 °C for 15 min, was stored at − 80 °C until analysis. IGF-I 
were measured using mouse IGF-I ELISA Kit (Abcam, cod: ab100695), following the manufacturers’ instruc-
tions. Results were assessed by colorimetric detection at 450 nm absorbance using LT-4000 microplate reader 
(Euroclone).
Statistical analysis. Statistical analysis was performed using GraphPad Prism version 5.01 for Windows 
(GraphPad Software, San Diego, CA, USA). All data were collected from each of the animals used in the experi-
mental procedure and means ± SEM were determined for each experimental group and analyzed by two-way 
analysis of variance (ANOVA) followed by Bonferroni post-hoc test. F values are referring to repeated measure 
2-way ANOVA. As for gene expression analysis, 1.00 (calibrator sample) was considered the theoretical mean 
for the comparison. Statistical significance was accepted at p < 0.05. As regards gene expression analysis, the 
comparative  2-ΔΔCt method was used to quantify the relative abundance of mRNA and then to determine the 
relative changes in individual gene expression (relative quantification)63. Number of animals randomized for 
each experimental group was calculated on the basis of the ‘Resource Equation’ N = (E + T)/T (10 ≤ E ≤ 20)68, 
according to the guidelines suggested by the ‘National Centre for the Replacement, Refinement and Reduction 
of Animals in Research’ (NC3RS) and reported on the following web site: https ://www.nc3rs .org.uk/exper iment 
al-desig nstat istic s.
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